Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA

Shripad Sinari; Juraj Koska; Yueming Hu; Jeremy D. Furtado; Majken K. Jensen; Matthew J. Budoff; Dobrin Nedelkov; Robyn L. McClelland; Dean Billheimer; Peter D. Reaven

doi:10.1161/atvbaha.123.319035

June 15, 2023Arteriosclerosis Thrombosis and Vascular BiologyOpen Access

Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore how different forms of Apo CIII relate to plasma lipids and cardiovascular disease risk.
Measured Apo CIII proteoforms in baseline plasma samples of 5791 participants using mass spectrometry immunoassay.
Collected standard plasma lipid data over up to 16 years and monitored cardiovascular events for up to 17 years.
Apo CIII proteoforms showed an inverse association with cardiovascular disease risk (HR 0.86 [0.79-0.93], p<0.001]).
Differences in demographic and clinical factors regarding Apo CIII proteoforms were identified, impacting lipid patterns and cardiovascular risk.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational study reveals links between Apo CIII proteoforms and cardiovascular risk in adults, suggesting implications for predicting health outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sinari et al. (2023) studied this question.

synapsesocial.com/papers/6a0661159fae39ec6e2af3b9 https://doi.org/10.1161/atvbaha.123.319035

View Full Paper

Ask AI

Bookmark

Share

Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading